Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells
Authors:
Open Access
- 16 December 2016
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-12
Abstract
Sialyltransferase I (ST6Gal-I) is an enzyme involved in tumor metastasis that processes sialic acid precursors into their mature form, enabling them to regulate gene expression. However, the effect of ST6Gal-I on the biological behavior of cancer cells remain unclear. This study was the first to demonstrate the influence of ST6Gal-I on cisplatin sensitivity in cervical cancer cells. Knockdown of ST6Gal-I was performed by shRNA and HeLa cells combination with cisplatin were tested. We showed that down-regulation of ST6Gal-I promoted cell apoptosis and inhibited proliferation and invasion in cervical cancer cells. Knockdown of ST6Gal-I by RNA interference increased the sensitivity of HeLa cells to cisplatin in vitro, and reduced tumor volume and suppressed subcutaneous tumor growth in response to cisplatin treatment in a xenograft mouse model in vivo. The results provide new information that ST6Gal-I plays an important role in several biological or pathological processes including drug resistance in cervical cancer and may be a potential therapeutic target to improve the response to chemotherapy in cervical cancer patients.Keywords
Funding Information
- NSFC (81071751, 81271078)
This publication has 47 references indexed in Scilit:
- Associations between antioxidant vitamins and the risk of invasive cervical cancer in Chinese women: A case-control studyScientific Reports, 2015
- Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivoInternational Journal of Nanomedicine, 2013
- Up-regulated miR155 Reverses the Epithelial-mesenchymal Transition Induced by EGF and Increases Chemo-sensitivity to Cisplatin in Human Caski Cervical Cancer CellsPLOS ONE, 2012
- Profiling of microRNA-mRNA reveals roles of microRNAs in cervical cancer.2012
- Treatment of early bulky cervical cancer with neoadjuvant paclitaxel, carboplatin and cisplatin prior to laparoscopical radical hysterectomy and pelvic lymphadenectomyOncology Letters, 2011
- Late Activation of Stress-activated Protein Kinases/c-Jun N-terminal Kinases Triggered by Cisplatin-induced DNA Damage in Repair-defective CellsJournal of Biological Chemistry, 2011
- Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung CancerJournal of Clinical Oncology, 2010
- The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cellsInternational Journal of Nanomedicine, 2009
- Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2–IIB cervical carcinomaGynecologic Oncology, 2007
- Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancerEuropean Journal of Cancer, 1998